Chronic Lymphocytic Leukemia

Higher mutational burden was linked to shorter time to first treatment in untreated patients with chronic lymphocytic leukemia independently of other genomic events, according to an abstract presented at ASH Annual Meeting and Exposition.

Time-limited dual B-cell receptor inhibitor therapy with acalabrutinib, umbralisib and ublituximab showed potential in treatment-naive and relapsed/refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Real-world data showed that Bruton tyrosine kinase inhibitors were a reasonable therapeutic option for patients with chronic lymphocytic leukemia and severe renal impairment, including for older adults and those on dialysis.

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.

Healio spoke with Ryan. W. Jacobs, MD, about challenges in the treatment of CLL.

Healio spoke with Ryan. W. Jacobs, MD, about potential causes and risk factors for developing CLL.

Healio spoke with Ryan. W. Jacobs, MD, about treatment options available to patients with CLL.

Healio spoke with Ryan. W. Jacobs, MD, about recent advancements in the management of CLL.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA announced several regulatory actions.